Episode
Quantum BioPharma’s Imaging Study With Massachusetts General Hospital — The MRI-to-PET Moment For Multiple Sclerosis
- Published
- May 26, 2026
- Duration seconds
- 1639
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/agoracom-small-cap-ceo-interviews-681672/episodes/quantum-biopharma-s-imaging-study-with-massachusetts-general-hospital-the-mri-to-pet-moment-for-multiple-sclerosis/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/agoracom-small-cap-ceo-interviews-681672/quantum-biopharma-s-imaging-study-with-massachusetts-general-hospital-the-mri-to-pet-moment-for-multiple-sclerosis.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
When a company proves it can see what others couldn’t, the rules of drug development change overnight. Quantum BioPharma announced on May 18, 2026, that patient enrollment has reached the halfway mark in its collaborative imaging study with Massachusetts General Hospital, accompanied by encouraging preliminary results using a novel PET imaging technique capable of directly assessing demyelinated neurons with intact axons. The company’s lead drug candidate, Lucid-MS, targets the underlying mechanism of multiple sclerosis—demyelination—rather than merely suppressing the immune system like most existing therapies. With an IND application submitted to the FDA on April 1, 2026, Quantum BioPharma is positioned at the intersection of breakthrough imaging science and first-in-class therapeutics. WHAT YOU NEED TO KNOW Imaging Leap: PET scanning with [18F]3F4AP tracer provides up to 10x more accuracy than conventional MRI in measuring myelin damage and repair—potentially establishing a new FDA biomarker standard. Halfway Validated: First cohort successfully imaged at MGH showing robust signal in acute MS lesions; study completion expected within six months. First-in-Class: Lucid-MS targets PAD2 enzyme to prevent and reverse myelin breakdown—preclinical models demonstrated ability to help animals regain lost mobility. Commercial Scale: MS therapeutic market projected to exceed $38 billion by 2030, affecting 2.8 million patients worldwide with no current therapies addressing mobility restoration. STRATEGIC IMPLICATIONS The MS treatment landscape is defined by what it cannot do. Virtually every approved therapy focuses on immune modulation—dampening the body’s attack on its own myelin. But none address the underlying destruction happening to nerve fibers, and none restore lost mobi…